ORIGINAL ARTICLE

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies

S Kasper¹, F Breitenbuecher¹, F Heidel², S Hoffarth¹, B Markova¹, M Schuler¹ and T Fischer²

Patients suffering from acute myeloid leukemias (AML) bearing FMS-like tyrosine kinase-3-internal tandem duplications (FLT3-ITD) have poor outcomes following cytarabine- and anthracyclin-based induction therapy. To a major part this is attributed to drug resistance of FLT3-ITD-positive leukemic cells. Against this background, we have devised an antibody array approach to identify proteins, which are differentially expressed by hematopoietic cells in relation to activated FLT3 signaling. Selective upregulation of antiapoptotic myeloid cell leukemia-1 (MCL-1) was found in FLT3-ITD-positive cell lines and primary mononuclear cells from AML patients as compared with FLT3-wild-type controls. Upregulation of MCL-1 was dependent on FLT3 signaling as confirmed by its reversion upon pharmacological inhibition of FLT3 activity by the kinase inhibitor PKC412 as well as siRNA-mediated suppression of FLT3. Heterologously expressed MCL-1 substituted for FLT3 signaling by conferring resistance of hematopoietic cells to antileukemia drugs such as cytarabine and daunorubicin, and to the proapoptotic BH3 mimetic ABT-737. Conversely, suppression of endogenous MCL-1 by siRNA or by flavopiridol treatment sensitized FLT3-ITD-expressing hematopoietic cells to cytotoxic and targeted therapeutics. In conclusion, MCL-1 is an essential effector of FLT3-ITD-mediated drug resistance. Therapeutic targeting of MCL-1 is a promising strategy to overcome drug resistance in FLT3-ITD-positive AML.

Blood Cancer Journal (2012) 2, e60; doi:10.1038/bcj.2012.5; published online 9 March 2012

Keywords: AML; MCL-1; FLT3-ITD; flavopiridol; resistance; kinase inhibitors

INTRODUCTION

Activating mutation of the FMS-like tyrosine kinase-3 receptor (FLT3) occurs in 30–40% of patients with acute myeloid leukemia (AML).¹,² Two different types of mutations have been described: internal tandem duplications (ITD) within the juxtamembrane domain and tyrosine kinase domain 1, and point mutations within the tyrosine kinase domain.¹³˚ Both types of mutations cause constitutive activation of the FLT3 receptor resulting in constitutive downstream signaling via the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and the phosphatidylinositol-3 kinase/AKT (PI3K/AKT) pathways. This may lead to enhanced cellular proliferation, reduced apoptosis and a block in the differentiation of hematopoietic blasts.¹⁶ In addition to canonical FLT3 downstream signaling, activation of further pathways has been described in FLT3-ITD-positive cells. Activation of signal transducer and activator of transcription 5 (STAT5) by FLT3-ITD is associated with increased expression of the antiapoptotic protein BCL-X_L as compared with FLT3-WT-expressing cells or cells harboring mutations of the FLT3 kinase domain.¹⁰

AML patients bearing FLT3-ITD mutations have a poor prognosis due to increased relapse rates following induction chemotherapy. This translates into reduced progression-free and overall survival rates as compared with the AML patients without ITD mutations.⁵,¹¹,¹２ Functionally, FLT3-ITD-expressing leukemic cells are more resistant to cytotoxic agents and residual blasts or at least FLT3-ITD-positive leukemic stem cells are thought to contribute to the higher relapse rate and the dismal outcome of FLT3-ITD-positive AML. Hence, targeting the aberrant FLT3-ITD receptor using specific tyrosine kinase inhibitors (TKIs) is a promising therapeutic approach.¹³,¹⁴ Several small molecule TKIs targeting FLT3 have been investigated in phase 1/2 clinical trials. Clinical responses have been observed with, midostaurin (PKC412), lestaurtinib (CEP-701), tandutinib (MLN-518) and SU11248, respectively, in chemotherapy refractory patients or patients not eligible for standard chemotherapy.¹₅–₂₀ Furthermore, FLT3-TKIs seem to resensitize FLT3-ITD-positive leukemic blasts to cytotoxic antileukemic drugs. Currently, combination therapies are under clinical investigation to translate these findings into clinical practice.²₀–₂₆ However, primary and secondary resistance mechanisms such as gatekeeper mutations interfering with drug target interaction or rewired signaling of the FLT3 receptor were observed in patients treated with FLT3 TKIs, which might interfere with this direct therapeutic strategy.²₅,²₆

Inhibition of aberrantly activated antiapoptotic pathways is one mechanism of action of FLT3-TKIs. This can result in direct induction of apoptotic death of FLT3-ITD-dependent leukemic cells. Further, this may lead to resensitization of FLT3-ITD-positive blasts and leukemic stem cells to conventional antileukemic drugs. In particular, upregulation of antiapoptotic members of the BCL-2 family has been described in FLT3-ITD-expressing cells.¹₄,²₇,²₈ BCL-2 family proteins are the main regulators of the ‘mitochondrial’ apoptosis pathway. They consist of anti- and proapoptotic proteins that determine the balance between survival and programmed cells death.²⁹ The antiapoptotic family members BCL-2, BCL-X_L, myeloid cell leukemia-1 (MCL-1), BCL-W and A1 counteract the apoptotic effector proteins BAX, BAK, and
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias
S Kasper et al

possibly BOK, to prevent their activation and mitochondrial outer membrane permeabilization leading to release of cytochrome c and subsequent caspase activation.\textsuperscript{56} Proapoptotic BH3 proteins, such as BAD, BIM, BIK, NOXA and PUMA, enable activation of BAX and BAK either by neutralizing antiapoptotic BCL-2 family proteins or by direct action.\textsuperscript{29} In many cancer types, the balance between pro- and antiapoptotic BCL-2 family members is disturbed. Frequently, this occurs as a consequence of aberrant activation of MEK/ERK, PI3K/AKT and/or STAT5 pathways.\textsuperscript{29,31}

Here, we have identified upregulation of the proapoptotic BCL-2 family member MCL-1 in FLT3-ITD-expressing cell lines and primary AML blasts as compared to FLT3-WT cells. Elevated MCL-1 RNA expression in FLT3-ITD-positive leukemic cells was suppressed by siRNA-mediated downregulation of the mutant receptor as well as by inhibitory concentrations of the protein kinase inhibitor PCK412. MCL-1 functionally contributed to the resistance phenotype of FLT3-ITD-positive leukemic cells. Suppression of endogenous MCL-1 by siRNA or by flavopiridol treatment sensitized FLT3-ITD cells to antileukemic therapies. These findings provide a rational basis for combination therapy strategies in FLT3-ITD-positive AML to eliminate residual leukemic blasts and stem cells after induction chemotherapy to overcome the poor prognosis of these patients.

MATERIALS AND METHODS

Cell models

Murine 32D cells were kindly provided by T Skorski (Philadelphia, PA, USA) and were maintained in RPMI 1640 with 10% fetal calf serum, 20 mmol/L HEPES, pH 7.3, 50 mmol/L β-mercaptoethanol, 2 mmol/L L-glutamine and 10% WEHI-3B-conditioned medium as a source of interleukin-3. The human AML cell lines MV4;11 and Molm-13 harboring a FLT3-ITD mutation and the human acute lymphoblastic leukemia cell line RS4;11 harboring the FLT3-WT receptor (all obtained from the DSMZ, Braunschweig, Germany) were maintained in RPMI 1640 with 10% fetal calf serum, 20 mmol/L HEPES, pH 7.3, 50 mmol/L β-mercaptoethanol and 2 mmol/L L-glutamine. All cells were grown at 37°C in a 5% CO₂-humidified incubator.\textsuperscript{32}

Isolation of primary AML blasts and FLT3-ITD mutation screening

Heparin-treated peripheral blood samples (20 ml) were obtained from 12 AML patients at the time of diagnosis or relapse. Informed consent was obtained in accordance with the Declaration of Helsinki. Mononuclear cells enriched in AML leukemic blasts were isolated as described.\textsuperscript{2} Genomic DNA from mononuclear cells was extracted using the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). ITD mutation screening by PCR was performed as described.\textsuperscript{2,3}

Plasmids, antibodies and reagents

The human FLT3-WT and a human FLT3-ITD construct, both subcloned into the pAL expression vector under control of the β globin long terminal repeat of the Moloney murine sarcoma virus (MoMSV) and the plasmid pMAM/BS/DS, were used as described previously and were a kind gift from H Serve (University of Frankfurt, Germany).\textsuperscript{3} This ITD allele (36 bp/12 amino acids) integrates between codons 598 and 599 in the JM domain of FLT3. The FLT3-ITD627E construct was subcloned into the pAL vector as described.\textsuperscript{25} The ITD627 allele (93 bp/31 aa) integrates between codons 627 and 628 of the j2 sheet of the tyrosine kinase domain 1 of FLT3 and leads to an amino-acid exchange at codon 627 (alanine to glutamate).\textsuperscript{8} The p3xFLAG-CMV10 vector containing the coding sequence of murine Mcl-1 under control of a CMV promotor was kindly provided by H Schulze-Bergkamen (National Center for Tumor Diseases, Heidelberg, Germany). All vector constructs were verified by nucleotide sequencing.

Flavopiridol was purchased from Sigma Aldrich (Munich, Germany), PCK412 was kindly provided by Novartis (Basel, Switzerland), ABT-737 was kindly provided by Abbott (Abbott Park, IL, USA); cytarabine and daunorubicin were purchased from the Hospital Pharmacy of the University Hospital Essen, Germany. ABT-737 was purchased from Abbott. Flavopiridol was purchased from Sigma Aldrich (Munich, Germany), PCK412 was kindly provided by Novartis (Basel, Switzerland), ABT-737 was kindly provided by Abbott (Abbott Park, IL, USA); cytarabine and daunorubicin were purchased from the Hospital Pharmacy of the University Hospital Essen, Germany.

The following primary antibodies were used: antiphospho-FLT3 (Y591), antiphospho-extracellular signal-related kinase 1/2 (ERK1/2; T202/Y204), anti-ERK1/2, antiphospho-S6 protein (S240/S244) and anti-S6 protein (all from Cell Signaling Technology, Danvers, MA, USA); anti-FLT3, anti-MCL-1, anti-BCL-XL (H5), anti-BCL-2 (C2) (all from Santa Cruz, Heidelberg, Germany), anti-Actin (MP Biomedicals, Aurora, OH, USA), anti-FLAG (M2) (Sigma Aldrich). Recombinant human interleukin-3 (IL3) was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), FLT3 ligand (FL) was purchased from R&D-Systems (Minneapolis, MN, USA).

Transfections

Transfection of 32D cells with different FLT3-DNA constructs was performed as described previously.\textsuperscript{2} Functional receptor expression was confirmed by immunoblotting and FACS analyses as described previously.\textsuperscript{3} 32D FLT3-ITD mMCL-1 cells and RS4;11 mMCL-1 cells, ectopically overexpressing MCL-1, were generated by transfection of 32D FLT3-ITD or Rs4;11 cells with 20 µg p3xFLAG-CMV10 vector containing the coding sequence of murine Mcl-1 by electroporation. Cells were selected with 0.5 mg/ml G418 and polyclonal cell lines were used for experiments.

Protein extract preparation and immunoblotting

Cells were serum starved for 5 h before treatment. 32D FLT3-WT and RS4;11 were treated with 100 ng/ml FL for 30 min. 32D FLT3-ITD, MV4;11 and Molm-13 cells were treated with flavopiridol or PCK412 in the indicated concentrations. Protein lysates were prepared for immunoblotting analyses as described previously.\textsuperscript{2,3}

Apoptosis assays

The percentage of apoptotic cells was determined by measuring the sub-G1 fraction upon propidium iodide incorporation using flow cytometry as described.\textsuperscript{2,3}

Drug combination index calculation

For calculation of combination indices (CI), cells were treated with flavopiridol, cytarabine, daunorubicin, ABT-737 and combinations of flavopiridol with the different drugs. Apoptotic cell death (fractional effect) was measured by flow cytometry. Pharmacological interaction of flavopiridol with cytarabine, daunorubicin and ABT-737 was analyzed using the CalcuSyn software (Biosoft, Cambridge, UK). CI ranging from 0.1 to 0.85 indicate strong to moderate synergism, indices from 0.85 to 0.9 slight synergism, indices from 0.9 to 1.1 nearly additive interaction and indices from 1.1 to 10 slight to strong antagonism, respectively.\textsuperscript{34}

Gene suppression by siRNA

MV4;11 2 × 10⁶ were transfected by electroporation with h-FLT3 (sIGEN-OEM SMARTpool, M-003137-01; Dharmacon, Lafayette, CO, USA), h-MCL-1 (sc-35877, Santa Cruz) specific siRNAs. siRNAs were dissolved to a final concentration of 20 µg stock solution and for each transfection 10 µl siRNA stock solution was used. As a negative control, an equivalent concentration of AllStars Negative Control siRNA (QIAGEN) was used. For verification of effective基因 suppression, protein lysates were prepared after 24 h and target protein expression was assayed by immunoblotting. For assessment of apoptosis, cells were left to recover from the transfection for 6 h and were then treated with or without cytarabine. Percentage of apoptotic cells was assessed following 24 h and 48 h incubation.

Proteomic analyses

32D FLT3-WT and FLT3-ITD were serum starved for 5 h. Cellular protein lysates of FL stimulated 32D FLT3-WT (100 ng/ml for 30 min) and non-stimulated 32D FLT3-ITD cells were prepared using lysis buffer, supplemented with protease and phosphatase inhibitors, supplied by Kinexus Bioinformatics (Vancouver, BC, Canada). Dye labeling, hybridization and analysis of the Kinex antibody array were done by Kinexus. Data obtained from the antibody array was filtered as follows: (1) Flag 0, this means spot quality is acceptable based on morphology and background; (2) change
from control (CFC): >20% or < -20% CFC, the percentage change from control is a measure of the change in normalized signal intensity averages between the experimental sample (32D FLT3-ITD) and the control sample (32D FLT3-WT + FL); (3) total error range: < 30%. The total error range is the sum of ‘% error range’ from the experimental and control samples; and (4) signal to noise (s/n) ratio: > 1.5. The s/n-ratio is the ratio between the measurement of the spot intensity and the spot’s local background.

Gene expression analysis
Cells were serum starved for 5 h before treatment with growth factors and inhibitors for the indicated time points. Total RNA was isolated using the High Pure RNA Isolation Kit protocol (Roche Diagnostics, Mannheim, Germany) and cDNA synthesis was performed according to the protocol of Transcription High Fidelity cDNA Synthesis Kit (Roche Diagnostics). An amount of 1-5 µg was transcribed with anchored-oligo(dT)18 primer. qRT-PCR was performed according to the protocol of SYBER Green 1 Master (Roche Diagnostics). The following primers were used for murine Mcl-1: 5'-TGCTAAACAAAGGAGCTGGATTG-3' and 5'-ATTGTCTAGCCGCCGCTTCA GGTC-3', human Mcl-1: 5'-AGAAGAACTGATGCAACAT-3' and 5'-CCAGCT CTCTACCTCAAGCAAC-3', human actin: 5'-TCAGCTGTGGGGTCCTGT-3' and 5'-GAGGGAAGCAGCGCTAGG-3', and GAPDH: 5'-GCCTCCACCACTGGAGA-3' and 5'-CGGCCATCAGCAGCAGTTT-3'.

RESULTS
Drug resistance of FLT3-ITD-expressing cells correlates with differential expression of antiapoptotic proteins
Leukemic cells expressing a mutant FLT3-ITD receptor were described to be resistant to chemotherapeutic drugs.13,14 In agreement, the FLT3-ITD-positive human leukemic cell line MV4;11 was more resistant to cytarabine-induced apoptosis as compared with the FLT3-WT cell line RS4;11 (data not shown). We hypothesized that activation of signal transduction pathways in FLT3-ITD-expressing cells accounted for this phenotype. To dissect differential protein expression and phosphorylation profiles in response to FLT3-ITD, we performed antibody array analyses (Kinex, Kinexus Bioinformatics) of the murine 32D cell line transfected with a wild-type human FLT3 (FLT3-WT 32D cells) or a mutant human FLT3-ITD receptor (FLT3-ITD 32D cells) constructs.5,22 Profiling was performed in FL-stimulated FLT3-ITD 32D cells and in untreated FLT3-ITD 32D cells using the Kinex platform, which allowed parallel analysis of expression and phosphorylation status of 615 different proteins (Figure 1a). We identified 85 differentially expressed/phosphorylated proteins in protein lysates from FLT3-ITD 32D cells as compared with FLT3-ITD 32D cells (Supplementary Tables 1A and B). A major proportion of these proteins was known to be involved in growth factor signal transduction. Based on the drug-resistant phenotype conferred by FLT3-ITD, we focused on proteins implied in the regulation of drug-induced apoptosis, such as the BCL-2 protein family.33,36 Antibody array analysis of the major antiapoptotic BCL-2 family proteins revealed a slight downregulation of BCL-2 (approximately 20%) and a robust upregulation of BCL-XL (by 40%) in FLT3-ITD 32D cells (Supplementary Table 1). Antibody array analysis of differential expression of MCL-1 was not feasible due to a low signal-to-noise ratio (data not shown). To confirm these results and determine MCL-1 expression levels, we performed immuno-blot analyses of protein lysates generated from FLT3-ITD RS4;11 cells stimulated with FL and from unstimulated FLT3-ITD MV4;11 cells, which supported the results concerning BCL-2 and BCL-XL obtained by the antibody array (Figures 1b and c). Interestingly, a significant upregulation of MCL-1 was observed in both FLT3-ITD models, MV4;11 cells and FLT3-ITD 32D cells, as compared to the respective FLT3-ITD controls or to parental 32D cells (Figure 1d). Interleukin-3 stimulation of parental 32D cells strongly induced MCL-1 protein expression (Figure 1d). In keeping, qRT-PCR analysis revealed more than fivefold higher MCL-1 transcript levels in FLT3-ITD-expressing MV4;11 and 32D cells as compared to FLT3-ITD RS4;11 and 32D cells (Figure 1e and data not shown). In addition to leukemic cell lines, we investigated MCL-1 protein levels in primary mononuclear cells from 12 AML patients. A pronounced MCL-1 expression was detected in all six patients harboring a FLT3-ITD mutation, whereas MCL-1 was only expressed in two out of six samples from FLT3-WT patients (Figure 1f).

MCL-1 is a downstream target of FLT3 receptor signaling
To study whether FLT3-ITD-mediated signal transduction leads to activation of MCL-1, we stimulated FLT3-WT RS4;11 and 32D cells with FL and analyzed MCL-1 RNA transcript levels and protein expression. MCL-1 transcript and protein levels were increased within 5 h of FL stimulation (Figures 2a and b). Conversely, RNAi-mediated suppression of the endogenous, constitutively active FLT3-ITD receptor in MV4;11 cells resulted in significant down-regulation of MCL-1 protein expression (Figure 2c). Taken together MCL-1 appears to be a direct downstream target of FL-stimulated FLT3 signaling as well as aberrantly activated FLT3-ITD in hematopoietic cells.

MCL-1 is an essential effector of FLT3-ITD-mediated drug resistance
To study the consequences of FLT3 inhibition at a functional level, we applied PKC412, a protein kinase inhibitor with activity against FLT3-ITD.37 Incubation of FLT3-ITD-expressing MV4;11 and 32D cells with PKC412 at a concentration of 100 nM led to dephosphorylation of the FLT3-ITD receptor and of S6 protein, a downstream target of FLT3-activated signaling (Figure 2d). This was accompanied by significant downregulation of MCL-1 in a time-dependent manner and induction of apoptosis (Figure 2d and data not shown). As expected, expression of a FLAG-tagged murine Mcl-1 cDNA (FLAG-Mcl-1) from a heterologous promoter in FLT3-ITD 32D cells was not affected by PKC412. PKC412 activity was evidenced by dephosphorylation of S6 protein (Figure 2e). Accordingly, FLT3-ITD 32D cells expressing FLAG-MCL-1 were significantly protected against PKC412-induced apoptosis (Figure 2f). Enforced FLAG-MCL-1 expression also conferred resistance to the cytotoxic agents cytarabine and daunorubicin, which are the mainstay of AML-induction therapy (Figures 2g and h).

Based on these findings MCL-1 constitutes a rational target for combination therapies overcoming drug resistance in FLT3-ITD-positive AML. To further explore this hypothesis, we devised siRNA specifically suppressing endogenous MCL-1 in FLT3-ITD-positive MV4;11 cells (Figure 3a). MCL-1 suppression was associated with enhanced spontaneous apoptosis and sensitization to cytarabine (Figure 3b). To confirm these findings in a clinically more applicable model, we used flavopiridol that has been described to inhibit MCL-1 transcription by disturbing the STAT3/DNA interaction.38 In phase I clinical trials in hematological diseases plasma levels up to 1.57 µM of flavopiridol could be achieved by a bolus-infusion in combination schedule.23 Therefore, concentrations ranging from 50 nM to 10 µM were used for further experiments. A dose-dependent downregulation of MCL-1 transcript levels by flavopiridol was achieved in FLT3-ITD-expressing MV4;11 cells and in an additional FLT3-ITD-positive leukemia model, Molm-13 (Figure 4a). In both models, suppression of MCL-1 transcript levels was associated with reduced MCL-1 protein expression (Figures 4b and c). To exclude non-specific downregulation of several BCL-2 family members by flavopiridol, we also analyzed the protein expression of BCL-2 and BCL-XL, which both remained unchanged (Figure 4c and data not shown). MCL-1 expression levels were reported to be regulated by MAPK signaling.40 Analyzing the basal phosphorylation levels of ERK1/2 by immunoblot using a phospho-specific antibody, we could not observe different MAPK pathway activation in...
FLT3-ITD-positive MV4;11 cells and FLT3-WT RS4;11. The phosphorylation status of ERK1/2 of MV4;11 and RS4;11 cells was not decreased by the presence or absence of flavopiridol (Figure 4d). This confirmed that flavopiridol had no impact on constitutive MAPK activation, an alternative mechanism of MCL-1 upregulation. To exclude interference of flavopiridol with FLT3 kinase activity, FLT3-ITD-positive MV4;11 cells were incubated with flavopiridol and PKC412 as positive control. No significant suppression of FLT3 receptor phosphorylation by flavopiridol was observed at concentrations as high as 10 \( \mu M \), whereas MCL-1 was completely suppressed by flavopiridol at concentrations of 200 \( \mu M \) and above (Figure 4e). Dephosphorylation of FLT3 by PKC412 was also associated with a reduction of MCL-1 protein level (Figure 4e).

Pharmacological targeting of MCL-1 in FLT3-ITD-positive AML

We hypothesized that downregulation of MCL-1 by flavopiridol could lead to enhanced apoptosis in FLT3-ITD-positive cells. Cell cycle analyses were performed in MV4;11, FLT3-ITD 32D and Molm-13 cells following incubation with increasing concentrations of flavopiridol. A dose-dependent induction of apoptosis was seen...
observed in all FLT3-ITD-positive cell lines (Figure 5a). Interestingly, flavopiridol also induced strong apoptosis in 32D cells expressing a non-JM FLT3-ITD receptor with an additional point mutation at position 627: These cells were shown to be resistant to PKC412 due to a differential signal transduction originating from an unusual FLT3-ITD receptor leading to upregulation of MCL-1 (Figure 5a). ABT-737 is a pharmacological BH3 mimetic that can induce apoptosis by neutralizing BCL-2 and BCL-XL. To study whether flavopiridol-mediated suppression of MCL-1 sensitized FLT3-ITD-positive MV4;11 and Molm-13 cells to ABT-737, we treated cells with ABT-737, flavopiridol or combinations of both. Although ABT-737 or flavopiridol alone were only moderately toxic, combination therapy was effectively inducing apoptosis in FLT3-ITD-expressing cell lines (Figures 5b and c and data not shown). To elucidate possible synergism between the two compounds, we calculated CI for a broad range of flavopiridol

Figure 2. MCL-1 upregulation is dependent on FLT3 receptor signaling. (a) MCL-1 RNA is upregulated in FLT3-WT cells following stimulation with FL. Semiquantitative RT-PCR analysis of FL (100 ng/ml for 5 h)-stimulated FLT3-WT expressing 32D cells using specific primers for murine Mcl-1. Expression was normalized to the housekeeping gene GAPDH. (b) MCL-1 is upregulated upon FL stimulation of FLT3-WT cells. Whole-cell lysates from FLT3-WT RS4;11 cells were analyzed by immunoblotting using a specific antibody for MCL-1 after stimulation with FL (100 ng/ml for 5 h). Reprobing with anti-Actin served as loading control. (c, d) Knockdown of the FLT3-ITD receptor by siRNA (c) or receptor tyrosine kinase inhibition by PKC412 (d) led to time dependent downregulation of MCL-1. FLT3 and MCL-1 expression was assessed in MV4;11 cells by immunoblotting 24 h after siRNA-mediated knockdown of FLT3 (c). 32D FLT3-ITD cells and MV4;11 cells were incubated with the FLT3-TKI PKC412 at a concentration of 100 nm for the indicated time periods. Whole-cell lysates were analyzed by immunoblotting using primary antibodies against phospho-FLT3, FLT3, phospho-S6 and MCL-1. Blots were reprobed for Actin expression to ensure equal protein loading. (e) Stable expression of a FLAG-tagged murine Mcl-1 cDNA (FLAG-MCL-1) led to sustained transgene expression in the presence of PKC412. Whole-cell lysates were obtained from FLAG-MCL-1-32D FLT3-ITD cells following incubation with PKC412 at different concentrations for 7 h, and were analyzed by immunoblotting using the indicated primary antibodies. (f) Expression of FLAG-MCL-1 confers resistance to PKC412. FLAG-MCL-1 32D FLT3-ITD cells were incubated with the indicated concentrations of PKC412 for 24 h. The percentage of apoptotic cells with subgenomic DNA was flow cytometrically assessed. Asterisks denote statistically significant ($P < 0.05$, t-test). (g, h) Expression of FLAG-MCL-1 confers resistance to cytarabine and daunorubicin. FLAG-MCL-1 32D FLT3-ITD cells were incubated for 24 h at the indicated drug concentrations. The percentage of apoptotic cells with subgenomic DNA was flow cytometrically assessed. Asterisks denote statistically significant ($P < 0.05$, t-test).
concentrations when combined with effective concentrations of ABT-737 (25 and 50 nM). A moderate to strong synergism was revealed for all combinations indicated by CI-values below 1 (Figure 5c and Table 1a). Next, we investigated whether flavopiridol-induced downregulation of MCL-1 sensitized FLT3-ITD-expressing cells to conventional cytotoxic drugs.FLT3-ITD 32D cells were incubated for 24 h with flavopiridol in combination with cytarabine or daunorubicin, respectively. Flavopiridol effectively sensitized FLT3-ITD-expressing cells to cytarabine- and daunorubicin-mediated apoptosis (Figures 6a-d). CI for flavopiridol and cytarabine (3 μM) or daunorubicin (100 nM) revealed moderate to strong synergism for all combinations (Figures 6b, d and Table 1b). To further establish downregulation of MCL-1 as the major mechanism of flavopiridol-induced cytotoxicity in FLT3-ITD-positive cells, we stably expressed FLAG-MCL-1 in FLT3-ITD 32D cells. At flavopiridol concentrations effectively suppressing endogenous MCL-1, heterologous FLAG-MCL-1 was still present in these double transgenic cell populations (Figure 7a). Interestingly, sustained expression of FLAG-MCL-1 mediated resistance to the proapoptotic effects of flavopiridol (Figure 7b). Additionally, FLAG-MCL-1-expressing cells were less susceptible to flavopiridol-mediated sensitization to cytarabine- or daunorubicin-induced apoptosis (Figures 7c to f). Only the highest concentration of flavopiridol synergized with cytarabine or daunorubicin (CI < 1), whereas all other combinations revealed only additive or even antagonistic effects (CI: 0.9 < CI < 1.1) (Figures 7d, f and Table 1b). Collectively these findings support the functional importance for MCL-1 in FLT3-ITD-mediated resistance of leukemia cells. Consequently, we proposed that MCL-1 could be targeted as an ‘Achilles’ heel’ in FLT3-ITD-driven AML.

**Figure 3.** Suppression of MCL-1 by siRNA sensitizes FLT3-ITD-positive cells to cytotoxic drugs. (a) MV4;11 cells were transfected with MCL-1-specific siRNA or scrambled control. Whole-cell lysates were analyzed for protein expression of MCL-1 and Actin (as loading control). (b) MV4;11 cells treated as in (a) were incubated with or without cytarabine (5 μM) for 24 h, and the fraction of apoptotic cells with subgenomic DNA was quantified by flow cytometry. Asterisks denote statistically significant (P < 0.05, t-test).

**Figure 4.** Flavopiridol suppresses MCL-1 in FLT3-ITD-positive cells. (a) Flavopiridol suppresses MCL-1 RNA expression in FLT3-ITD-positive cells. MV4;11 and Molm13 cells were incubated for 5 h with flavopiridol at several concentrations, followed by RNA extraction and reverse transcription. Expression of MCL-1 and Beta-Actin was measured by qRT-PCR; MCL-1 levels were normalized to Beta-Actin. Values were related to the untreated medium control. (B) Dose-dependent suppression of MCL-1 protein expression in FLT3-ITD-positive cells by flavopiridol. MV4;11 cells were incubated for 5 h with flavopiridol at incremental concentrations. Whole-cell lysates were analyzed for MCL-1 and Actin expression (as loading control) by immunoblotting. (c) Flavopiridol suppresses MCL-1 but not BCL-2 in FLT3-ITD-positive cells. MV4;11 and Molm-13 cells were incubated for 5 h with flavopiridol at incremental concentrations. Whole-cell lysates were analyzed for expression of MCL-1, BCL-2 and Actin (as loading control) by immunoblotting. Flavopiridol used at MCL-1-suppressing concentrations does not act on MAPK activation (d) or FLT3 autophosphorylation (e). MV4;11 and RS4;11 cells were incubated for 5 h with flavopiridol at incremental concentrations or PKC412 100 nm, respectively. Whole-cell lysates were analyzed by immunoblotting for expression of p-ERK, ERK and Actin (d) or p-FLT3, FLT3, MCL-1 and Actin (e).
incubated for 48 h with flavopiridol (25, 50, 100, 200 and 500 nM) or ABT-737 (25 or 50 nM), respectively. Nearly additive interaction and indices from 1.1 to 10 slight to strong synergism, indices from 0.85 to 0.9 slight synergism, indices from 0.9 to 1.1 ranging from 0.1 to 0.85 indicate strong to moderate synergism, indices for all treatments are listed in Table 1a. Combination indices were calculated using the CalcuSyn software; normalized isobolograms are represented. The actual combination of anticancer agents in FLT3-ITD-positive cells. MV4;11, Molm-13, 32D FLT3-ITD and 32D FLT3-ITD_627E cells were incubated with flavopiridol at the indicated concentrations for 24 h (MV4;11 and 32D) or 48 h (Molm-13). The percentage of apoptotic cells with subgenomic DNA was assessed by flow cytometry. (b) MV4;11 cells were incubated for 48 h with flavopiridol (FP), ABT-737 or combinations thereof, and the percentage of apoptotic cells with subgenomic DNA was assessed by flow cytometry. (c) MV4;11 cells were incubated for 48 h with flavopiridol (25, 50, 100, 200 and 500 nM) or ABT-737 (10, 25, 50, 100, 200 and 500 nM). In addition, cells were incubated with flavopiridol (25, 50, 100 and 200 nM) in combination with ABT-737 (25 or 50 nM). Percentage of apoptotic cells with subgenomic DNA (fractional effect) was assessed by flow cytometry. Combination indices were calculated using the CalcuSyn software; normalized isobolograms are represented. The actual combination indices for all treatments are listed in Table 1a. Combination indices ranging from 0.1 to 0.85 indicate strong to moderate synergism, indices from 0.85 to 0.9 slight synergism, indices from 0.9 to 1.1 nearly additive interaction and indices from 1.1 to 10 slight to strong antagonism, respectively.

**Figure 5.** Activity of flavopiridol monotherapy and in combination with anticancer agents in FLT3-ITD-positive cells. (a) MV4;11, Molm-13, 32D FLT3-ITD and 32D FLT3-ITD_627E cells were incubated with flavopiridol, ABT-737 or combinatorial therapies in our FLT3-ITD-positive cells, the exact mechanism how MCL-1 overexpression is linked to activation of FLT3 has to be clarified at this point. Recently, Yoshimoto et al. 14 observed a FLT3-ITD-dependent upregulation of MCL-1 in primary leukemic stem cells via activation of STAT5. In our cell models a STAT5-dependent upregulation of MCL-1 seems unlikely because FL stimulation of wild-type FLT3-expressing cells also enhanced MCL-1 RNA transcription and protein levels, while STAT5 is not known to be activated by the wild-type FL-stimulated FLT3 receptor. Using siRNA approaches or the MEK/ERK inhibitor U0126, we recently demonstrated that suppression of STAT3 or inhibition of the MAPK/ERK pathway had no impact on MCL-1 expression in FLT3-ITD_627E cells, making this mode of action questionable in the present models of FLT3-ITD-positive hematopoietic cells. However, even though the exact mechanisms how deregulated MCL-1 expression is linked to activation of FLT3 needs to be determined, inhibition of overexpressed MCL-1 might be a promising therapeutic approach to sensitize residual blasts or leukemic stem cells to chemotherapy and to overcome the poor prognosis of FLT3-ITD-positive AML patients. This could be achieved by ‘non-targeted’ agents like flavopiridol, a semisynthetic flavonoid flavopiridol, which is derived from the indigenous Indian plant Dysoxylum binectariferum. Originally being described as an inhibitor of cyclin-dependent kinases, flavopiridol was shown here to be a potent inhibitor of RNA and protein expression of MCL-1, but not BCL-2 or BCL-XL, in FLT3-ITD-positive cells. Flavopiridol was described to disrupt the STAT3/DNA-binding, leading to reduced transcription of STAT3-induced genes. As suppression of STAT3 had no impact on MCL-1 expression, though in FLT3-ITD_627E cells presumably showing a different signaling, this mode of action might not apply to our present models. Additionally, we excluded inhibition of the MAPK/ERK-pathway, which reportedly can be involved in MCL-1 upregulation, as well as inhibition of the FLT3 receptor kinase by flavopiridol. However, flavopiridol sensitized FLT3-ITD-expressing cells to the cytotoxic drugs cytarabine and daunorubicin and to targeted therapies like the BH3-mimetic drug ABT-737, which was described to be ineffective in MCL-1-overexpressing cells. 35,41 Although at this point the exact mechanism for MCL-1 suppression by flavopiridol remains to be clarified, the compound could serve as a model for the development of more specific MCL-1-targeting agents to eliminate residual FLT3-ITD leukemic blasts and stem cells that are resistant to cytotoxic agents.

**DISCUSSION**

Here, we identify the antiapoptotic protein MCL-1 as promising target in FLT3-ITD-positive leukemia. MCL-1 expression was found to be increased in FLT3-ITD-positive leukemic cell lines and primary AML blasts compared with FLT3 wild-type controls and was strictly dependent on FLT3 signaling as confirmed by its reversion upon pharmacological inhibition of FLT3 activity as well as siRNA-mediated suppression of FLT3. As patients harboring FLT3-ITD mutations have a worse prognosis with higher relapse rates, reduced disease-free and overall survival rates compared to patients harboring wild-type FLT3, we assume that MCL-1 contributes to chemotherapeutic resistance of residual FLT3-ITD-positive blasts and/or leukemic stem cells. In fact, we and others observed a reduced sensitivity to the cytotoxic drug cytarabine in myeloid leukemic cells transfected with a FLT3-ITD receptor. Heterologously expressed MCL-1 substituted for FLT3 signaling by conferring resistance of hematopoietic cells to antileukemia drugs such as cytarabine and daunorubicin, and to the proapoptotic BH3 mimetic ABT-737. Conversely, suppression of endogenous MCL-1 by siRNA or by flavopiridol treatment sensitized FLT3-ITD-expressing hematopoietic cells to chemotherapy and targeted therapeutics.
| FP [nM] | ABT-737 [nM] | CI MV4;11 |
|---------|--------------|-----------|
| 25      | 25           | 0.346     |
| 50      | 25           | 0.290     |
| 100     | 25           | 0.418     |
| 200     | 25           | 0.705     |
| 25      | 50           | 0.288     |
| 50      | 50           | 0.327     |
| 100     | 50           | 0.543     |
| 200     | 50           | 0.872     |

| FP [nM] | Ara-C [µM] | CI 32D FLT3-ITD | CI 32D FLT3-ITD MCL-1/FLAG |
|---------|------------|----------------|---------------------------|
| 25      | 3          | 0.563          | 4.668                     |
| 50      | 3          | 0.378          | 2.789                     |
| 100     | 3          | 0.780          | 4.486                     |
| 200     | 3          | 0.421          | 0.507                     |

| FP [nM] | DNR [nM]   | CI 32D FLT3-ITD | CI 32D FLT3-ITD MCL-1/FLAG |
|---------|------------|----------------|---------------------------|
| 25      | 100        | 0.583          | 1.046                     |
| 50      | 100        | 0.415          | 0.936                     |
| 100     | 100        | 0.409          | 1.011                     |
| 200     | 100        | 0.904          | 0.778                     |

Abbreviations: Ara-C, cytarabine; DNR, daunorubicin; FP, flavopiridol. Combination indices ranging from 0.1 to 0.3 indicate strong synergism, indices from 0.3 to 0.7 indicate synergism, indices from 0.7 to 0.85 indicate moderate synergism, indices from 0.85 to 0.9 slight synergism, indices from 0.9 to 1.1 nearly additive interaction, indices from 1.1 to 1.2 slight antagonism, indices from 1.2 to 1.45 moderate antagonism, indices from 1.45 to 3.3 antagonism and from 3.3 to 10 strong antagonism, respectively.

Figure 6. Activity of flavopiridol in combination with cytotoxic drugs in FLT3-ITD-positive cells. 32D FLT3-ITD-positive cells were incubated for 24 h with flavopiridol (FP), cytarabine (Ara-C) (a), daunorubicin (DNR) (c) or combinations thereof. The percentage of apoptotic cells with subgenomic DNA was assessed by flow cytometry. (b, d) 32D FLT3-ITD cells were incubated for 24 h with flavopiridol (25, 50, 100, 200 and 500 nM), cytarabine (1, 2, 3, 5, 10 and 20 µM) or daunorubicin (25, 50, 100, 150, 200 and 500 nM). In addition, cells were incubated with flavopiridol (25, 50, 100 and 200 nM) in combination with cytarabine (3 µM) (b) or daunorubicin (100 nM) (d). Percentage of apoptotic cells with subgenomic DNA (fractional effect) was assessed by flow cytometry. Combination indices were calculated using the CalcuSyn software; normalized isobolograms are represented. The actual combination indices for all treatments are listed in Table 1b. Combination indices ranging from 0.1 to 0.85 indicate strong to moderate synergism, indices from 0.85 to 0.9 slight synergism, indices from 0.9 to 1.1 nearly additive interaction and indices from 1.1 to 10 slight to strong antagonism, respectively.
CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We thank Henning Schulze-Bergkamen (Heidelberg, Germany) and Frank Boehmer (Jena, Germany) for providing reagents. This work was funded by grants from the ‘Deutsche Krebshilfe’ (#108218, TF) and a CESAR Research Fellowship (SK) and the IFORES program of the Medical Faculty of the University Duisburg-Essen (MS).

REFERENCES
1 Nakao M, Yokota S, Iwai T, Kameko H, Honike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.
2 Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665.
3 Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434–2439.

Figure 7. MCL-1 protects FLT3-ITD-positive cells against the proapoptotic activity of flavopiridol. (a) 32D FLT3-ITD cells were transfected to stably express a FLAG-MCL-1 construct or control vector. Expression of endogenous MCL-1 and transgenic FLAG-MCL-1 in relation to flavopiridol (FP, 5 h) treatment was assessed by immunoblotting. Actin was probed as loading control. (b) Expression of FLAG-MCL-1 rescues FLT3-ITD-positive cells from flavopiridol-induced apoptosis. 32D FLT3-ITD cells transfected with FLAG-MCL-1 or control vectors were incubated for 24 h with flavopiridol (FP) at incremental concentrations. The percentage of apoptotic cells with subgenomic DNA was quantified by flow cytometry. Asterisks denote statistically significant (P < 0.05, t-test). (c, e) Expression of FLAG-MCL-1 protects FLT3-ITD-positive cells against apoptosis induced by cytarabine (Ara-C) (c), daunorubicin (DNR) (e) alone and in combination with flavopiridol (FP). 32D FLT3-ITD cells transfected with FLAG-MCL-1 or control vectors were incubated for 24 h with flavopiridol (FP), cytarabine (Ara-C), daunorubicin (DNR) or combinations thereof. The percentage of apoptotic cells with subgenomic DNA was quantified by flow cytometry. (d, f) 32D FLT3-ITD cells transfected with FLAG-MCL-1 or control vectors were incubated for 24 h with flavopiridol (25, 50, 100, 200 and 500 nM), cytarabine (1,2,3,5,10 and 20 μM) or daunorubicin (25, 50, 100, 150, 200 and 500 nM). In addition, cells were incubated with flavopiridol (25, 50, 100 and 200 nM) in combination with cytarabine (3 μM) (d) or daunorubicin (100 nM) (f). Percentage of apoptotic cells with subgenomic DNA (fractional effect) was assessed by flow cytometry. Combination indices were calculated using the CalcuSyn software; normalized isobolograms are represented. The actual combination indices for all treatments are listed in Table 1b. Combination indices ranging from 0.1 to 0.85 indicate strong to moderate synergism, indices from 0.85 to 0.9 slight synergism, indices from 0.9 to 1.1 nearly additive interaction and indices from 1.1 to 10 slight to strong antagonism, respectively.

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias
S Kasper et al
Blood Cancer Journal
© 2012 Macmillan Publishers Limited
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias

S Kasper et al

4. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.

5. Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 2005; 105: 335–340.

6. Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brechi A et al. Identification of a novel type of ITD mutations located in nonjunctamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009; 113: 4074–4077.

7. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF et al. Ligand for FLT3/Flk2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643–648.

8. Mizuki M, Fenski R, Halfier H, Matsumura I, Schmidt R, Muller C et al. FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells meditated by the Ras and STATS pathways. Blood 2000; 96: 3907–3914.

9. Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006; 203: 371–381.

10. Speikermann K, Bagrintseva K, Schwib R, Schmijek J, Hiddemann W. Over-expression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003; 9: 2140–2150.

11. Thiede C, Steudel C, Mohr B, Schach M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335.

12. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918.

13. Jin G, Matsuhashi H, Asai S, Tsukamoto H, Ono R, Nosaka T et al. FLT3-ITD induces ara-C resistance in myeloid leukemia cells through the repression of the ENT1 expression. Biochim Biophys Acta Commun 2009; 390: 1001–1006.

14. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, lino T, Rocnik JL, Kikushige Y et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009; 114: 5034–5043.

15. Stone RM, Deangelo DJ, Klimak V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54–60.

16. Smith BD, Levin M, Beran J, Giles F, Kasper S et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009; 114: 3674–3681.

17. O’Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA et al. FLT3 as a therapeutic target in AML: still challenging. J Exp Med 2009; 206: 1901–1906.

18. Kindler T, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-667 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293–300.

19. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T et al. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003; 102: 2969–2975.

20. Kiel TM, Hellingier C, Ahmed F, Bode K, Hiddemann W, Bohlander SK et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007; 21: 1763–1772.

21. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005; 8: 5–6.

22. Chipuk JE, Motolouana T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 39: 299–310.

23. Kindler T, Breitenbuecher F, Kasper S, Edwards R, Bohrer FD et al. Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation. J Interferon Cytokine Res 2007; 27: 947–959.

24. Kindler T, Breitenbuecher F, Kasper S, Stevens R, Carius B, Schmaierhead H et al. In BCR-ABL-positive cells, STAT5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 2003; 17: 999–1009.

25. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440–446.

26. Wesang E, Hoffarth S, Wiedott R, Kroll M, Bierfelder S, Huber C et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007; 121: 2387–2394.

27. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690–694.

28. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433–443.

29. Lee YK, Isham CR, Kaufman SH, Bible KC. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther 2005; 138: 138–148.

30. Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M et al. Phase 1 and pharmacokinetic study of boc-1-flavopiridol flavopiridol followed by cytotoxic arabinoside and mitomycin for acute leukemias. Blood 2011; 117: 3302–3310.

31. Kindler T, Breitenbuecher F, Kasper S, Edwards R, Carius B et al. Phase 1 and pharmacokinetic study of boc-2-flavopiridol flavopiridol followed by cytotoxic arabinoside and mitomycin for acute leukemias. Blood 2011; 117: 3302–3310.

32. Huang XM, Hua RJ, Yin JY, Mei-1 is a common target of stem cell factor and interleukin-3 for apoptosis prevention activity via MEP/MEK and PI3K/Akt pathways. Blood 2006; 96: 1764–1771.

33. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375–388.

34. Pardee TS, Zuber J, Lowe SW. FLT3-ITD alters chemotherapy resistance in vitro and in vivo in a p53-dependent manner. Exp Hematol 2011; 39: 473–485.

35. Choudhary C, Schwabe J, Brands J, Tickenbrock L, Sargin B, Kindler T et al. AML-associated FLT3 kinase domain mutations show signal transduction differences compared with FLT3 ITD mutations. Blood 2005; 106: 265–273.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

Supplementary Information accompanies the paper on Blood Cancer Journal website (http://www.nature.com/bcj)